BACKGROUND: Infants with acute lymphoblastic leukemia (ALL) have a poor prognosis. Intensification of therapy has resulted in fewer relapses but increased early deaths, resulting in failure to improve survival. PROCEDURE: AALL0631 is a Phase 3 study for infants (<366 days of age) with newly diagnosed ALL. Induction initially (Cohort 1) consisted of 3 weeks of therapy based on COG P9407. Due to excessive early mortality, induction was amended to a less intensive 5 weeks of therapy based on Interfant-99. Additionally, enhanced supportive care guidelines were incorporated with hospitalization during induction until evidence of marrow recovery and recommendations for prevention/treatment of infections (Cohort 2). RESULTS: Induction mortality was significantly lower for patients in Cohort 2 (2/123, 1.6%) versus Cohort 1 (4/26, 15.4%; P = 0.009). All induction deaths were infection related except one due to progressive disease (Cohort 2). Sterile site infections were lower for patients in Cohort 2 (24/123, 19.5%) versus Cohort 1 (15/26, 57.7%; P = 0.0002), with a significantly lower rate of Gram positive infections during induction for patients in Cohort 2, P = 0.0002. No clinically significant differences in grades 3-5 non-infectious toxicities were observed between the two cohorts. Higher complete response rates were observed at end induction intensification for Cohort 2 (week 9, 94/100, 94%) versus Cohort 1 (week 7, 17/25, 68%; P = 0.0.0012). CONCLUSION: De-intensification of induction therapy and enhanced supportive care guidelines significantly decreased induction mortality and sterile site infections, without decreasing complete remission rates.
BACKGROUND:Infants with acute lymphoblastic leukemia (ALL) have a poor prognosis. Intensification of therapy has resulted in fewer relapses but increased early deaths, resulting in failure to improve survival. PROCEDURE: AALL0631 is a Phase 3 study for infants (<366 days of age) with newly diagnosed ALL. Induction initially (Cohort 1) consisted of 3 weeks of therapy based on COG P9407. Due to excessive early mortality, induction was amended to a less intensive 5 weeks of therapy based on Interfant-99. Additionally, enhanced supportive care guidelines were incorporated with hospitalization during induction until evidence of marrow recovery and recommendations for prevention/treatment of infections (Cohort 2). RESULTS: Induction mortality was significantly lower for patients in Cohort 2 (2/123, 1.6%) versus Cohort 1 (4/26, 15.4%; P = 0.009). All induction deaths were infection related except one due to progressive disease (Cohort 2). Sterile site infections were lower for patients in Cohort 2 (24/123, 19.5%) versus Cohort 1 (15/26, 57.7%; P = 0.0002), with a significantly lower rate of Gram positive infections during induction for patients in Cohort 2, P = 0.0002. No clinically significant differences in grades 3-5 non-infectious toxicities were observed between the two cohorts. Higher complete response rates were observed at end induction intensification for Cohort 2 (week 9, 94/100, 94%) versus Cohort 1 (week 7, 17/25, 68%; P = 0.0.0012). CONCLUSION: De-intensification of induction therapy and enhanced supportive care guidelines significantly decreased induction mortality and sterile site infections, without decreasing complete remission rates.
Authors: G H Reaman; R Sposto; M G Sensel; B J Lange; J H Feusner; N A Heerema; M Leonard; E J Holmes; H N Sather; T W Pendergrass; H S Johnstone; R T O'Brien; P G Steinherz; P M Zeltzer; P S Gaynon; M E Trigg; F M Uckun Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: M Dördelmann; A Reiter; A Borkhardt; W D Ludwig; N Götz; S Viehmann; H Gadner; H Riehm; M Schrappe Journal: Blood Date: 1999-08-15 Impact factor: 22.113
Authors: L S Frankel; J Ochs; J J Shuster; R Dubowy; W P Bowman; M Hockenberry-Eaton; M Borowitz; A J Carroll; C P Steuber; D J Pullen Journal: J Pediatr Hematol Oncol Date: 1997 Jan-Feb Impact factor: 1.289
Authors: L B Silverman; T W McLean; R D Gelber; M J Donnelly; D G Gilliland; N J Tarbell; S E Sallan Journal: Cancer Date: 1997-12-15 Impact factor: 6.860
Authors: Bruce C Bostrom; Martha R Sensel; Harland N Sather; Paul S Gaynon; Mei K La; Katherine Johnston; Gary R Erdmann; Stuart Gold; Nyla A Heerema; Raymond J Hutchinson; Arthur J Provisor; Michael E Trigg Journal: Blood Date: 2003-01-16 Impact factor: 22.113
Authors: A Ferster; Y Bertrand; Y Benoit; A Boilletot; C Behar; G Margueritte; A Thyss; A Robert; F Mazingue; G Souillet Journal: Br J Haematol Date: 1994-02 Impact factor: 6.998
Authors: Joanne M Hilden; Patricia A Dinndorf; Sharon O Meerbaum; Harland Sather; Doojduen Villaluna; Nyla A Heerema; Ron McGlennen; Franklin O Smith; William G Woods; Wanda L Salzer; Helen S Johnstone; Zoann Dreyer; Gregory H Reaman Journal: Blood Date: 2006-03-23 Impact factor: 22.113
Authors: Tamara P Miller; Kelly D Getz; Yimei Li; Biniyam G Demissei; Peter C Adamson; Todd A Alonzo; Evanette Burrows; Lusha Cao; Sharon M Castellino; Marla H Daves; Brian T Fisher; Robert Gerbing; Robert W Grundmeier; Edward M Krause; Judy Lee; Philip J Lupo; Karen R Rabin; Mark Ramos; Michael E Scheurer; Jennifer J Wilkes; Lena E Winestone; Douglas S Hawkins; M Monica Gramatges; Richard Aplenc Journal: Lancet Haematol Date: 2022-07-20 Impact factor: 30.153
Authors: Azada Ibrahimova; Lena E Winestone; Tamara P Miller; Kyle Kettler; Alix E Seif; Yuan-Shung Huang; Caitlin W Elgarten; Regina M Myers; Brian T Fisher; Richard Aplenc; Kelly D Getz Journal: Pediatr Blood Cancer Date: 2021-03-11 Impact factor: 3.167
Authors: Ashley V Geerlinks; Thomas Issekutz; Justin T Wahlstrom; Kathleen E Sullivan; Morton J Cowan; Christopher C Dvorak; Conrad V Fernandez Journal: Pediatr Blood Cancer Date: 2016-06-29 Impact factor: 3.167
Authors: Joseph P Loftus; Anella Yahiaoui; Patrick A Brown; Lisa M Niswander; Asen Bagashev; Min Wang; Allyson Schauf; Stacey Tannheimer; Sarah K Tasian Journal: Haematologica Date: 2021-04-01 Impact factor: 9.941